We use cookies to help us improve the website and your experience using it. You may delete and block all cookies from this site at any time. However, please note this may result in parts of the site no longer working correctly. If you continue without changing your settings we will assume you are happy to receive all cookies on this site.


Drug resistance

The availability of 2nd and 3rd plus generation drugs etc, their appropriate usage, and the occurrence of resistance to therapy due to the presence of ABL kinase domain mutations, requires additional testing.

We can send appropriate samples for an ABL kinase domain mutation screen to our collaborators, on behalf of referrers.

The current testing is applied to mutations occurring in the ABL kinase gene. This does not exclude other mechanisms of resistance that have been documented.


(Last reviewed 12th February 2018)